Skip to main content
. 2018 Dec;7(6):616–630. doi: 10.21037/tlcr.2018.08.01

Figure 1.

Figure 1

Suitability of TML panel’s size and targets in assessing TMB. (A) Comparison of somatic mutations by WES with somatic mutations covered by TML panel. This pan-cancer in-silico analysis was performed on 21,056 exomes from COSMIC v80 covering more than 22 cancer types; (B) in-silico comparison of somatic mutations by TML with that from WES for four common cancer types: colorectal, melanoma, lung, and endometrial cancer. Next, exomes from three separate cohorts were downloaded, and for each exome, TML panel covered somatic mutations were used to stratify responders and non-responders to obtain high statistical significance in, (C) NSCLC (ref. Rizvi; P=0.00568); (D) melanoma (ref. Snyder; P=0.000348), and (E) melanoma (ref. Van; P=0.00498). TML, tumor mutation load; TMB, tumor mutational burden; WES, whole exome sequencing; NSCLC, non-small cell lung cancer.